LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...

The increase in quarterly revenues continues to strengthen Mesoblast's balance sheet after the Company announced it entered into a US$125 million facility with its largest shareholder which ...

Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, is pleased to announce the promotion of Lawrence "Larry" Pitcher to Chief Executive Officer, ...

A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, ...

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P.

Clonell launches the world’s first patient-specific embryonic stem cell therapy platform, aimed at incurable diseases with ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

SCD gene therapy approaches using CRISPR, gene therapy, and base editing show different stem cell outcomes in a mouse study.

Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

A clinical-stage biotechnology company headquartered in New York, United States. The company runs clinical development ...